Search

Your search keyword '"Zecca, Chiara"' showing total 745 results
Start Over Author "Zecca, Chiara"
745 results on '"Zecca, Chiara"'

52. Incidence of Syndromes Associated With Frontotemporal Lobar Degeneration in 9 European Countries

Author

the FRONTIERS group, Logroscino, Giancarlo, Piccininni, Marco, Graff, Caroline, Hardiman, Orla, Ludolph, Albert C., Moreno, Fermin, Otto, Markus, Remes, Anne M., Rowe, James B., Seelaar, Harro, Solje, Eino, Stefanova, Elka, Traykov, Latchezar, Jelic, Vesna, Rydell, Melissa Taheri, Pender, Niall, Anderl-Straub, Sarah, Barandiaran, Myriam, Gabilondo, Alazne, Kruger, Johanna, Murley, Alexander G., Rittman, Timothy, van der Ende, Emma L., van Swieten, John C., Hartikainen, Paeivi, Stojmenovic, Gorana Mandic, Mehrabian, Shima, Benussi, Luisa, Alberici, Antonella, Dell'Abate, Maria Teresa, Zecca, Chiara, Borroni, Barbara, Neurology, Department of Neurosciences, Faculty of Medicine, Clinicum, HUS Neurocenter, Belezhanska, Diyana, Bianchetti, Angelo, Binetti, Giuliano, Cotelli, Maria, Cotelli, Maria Sofia, Dreharova, Irena, Filardi, Marco, Fostinelli, Silvia, Ghidoni, Roberta, Gnoni, Valentina, Nacheva, Genoveva, Novaković, Ivana, Padovani, Alessandro, Popivanov, Ivo, Raycheva, Margarita, Stockton, Katherine, Stoyanova, Katya, Suhonen, Noora-Maria, Tainta, Mikel, Toncheva, Draga, Urso, Daniele, Zlatareva, Dora, and Zulaica, Miren

Subjects
Subtypes, Amyotrophic-lateral-sclerosis, Diagnosis, Prevalence, Pathology, Dementia, ddc:610, Neurology (clinical), Criteria, 3124 Neurology and psychiatry
Abstract

ImportanceDiagnostic incidence data for syndromes associated with frontotemporal lobar degeneration (FTLD) in multinational studies are urgent in light of upcoming therapeutic approaches.ObjectiveTo assess the incidence of FTLD across Europe.Design, Setting, and ParticipantsThe Frontotemporal Dementia Incidence European Research Study (FRONTIERS) was a retrospective cohort study conducted from June 1, 2018, to May 31, 2019, using a population-based registry from 13 tertiary FTLD research clinics from the UK, the Netherlands, Finland, Sweden, Spain, Bulgaria, Serbia, Germany, and Italy and including all new FTLD-associated cases during the study period, with a combined catchment population of 11 023 643 person-years. Included patients fulfilled criteria for the behavioral variant of frontotemporal dementia (BVFTD), the nonfluent variant or semantic variant of primary progressive aphasia (PPA), unspecified PPA, progressive supranuclear palsy, corticobasal syndrome, or frontotemporal dementia with amyotrophic lateral sclerosis (FTD-ALS). Data were analyzed from July 19 to December 7, 2021.Main Outcomes and MeasuresRandom-intercept Poisson models were used to obtain estimates of the European FTLD incidence rate accounting for geographic heterogeneity.ResultsBased on 267 identified cases (mean [SD] patient age, 66.70 [9.02] years; 156 males [58.43%]), the estimated annual incidence rate for FTLD in Europe was 2.36 cases per 100 000 person-years (95% CI, 1.59-3.51 cases per 100 000 person-years). There was a progressive increase in FTLD incidence across age, reaching its peak at the age of 71 years, with 13.09 cases per 100 000 person-years (95% CI, 8.46-18.93 cases per 100 000 person-years) among men and 7.88 cases per 100 000 person-years (95% CI, 5.39-11.60 cases per 100 000 person-years) among women. Overall, the incidence was higher among men (2.84 cases per 100 000 person-years; 95% CI, 1.88-4.27 cases per 100 000 person-years) than among women (1.91 cases per 100 000 person-years; 95% CI, 1.26-2.91 cases per 100 000 person-years). BVFTD was the most common phenotype (107 cases [40.07%]), followed by PPA (76 [28.46%]) and extrapyramidal phenotypes (69 [25.84%]). FTD-ALS was the rarest phenotype (15 cases [5.62%]). A total of 95 patients with FTLD (35.58%) had a family history of dementia. The estimated number of new FTLD cases per year in Europe was 12 057.Conclusions and RelevanceThe findings suggest that FTLD-associated syndromes are more common than previously recognized, and diagnosis should be considered at any age. Improved knowledge of FTLD incidence may contribute to appropriate health and social care planning and in the design of future clinical trials.

Published
2023

53. Synthesizing cross‐design evidence and cross‐format data using network meta‐regression

Author

Hamza, Tasnim, Chalkou, Konstantina, Pellegrini, Fabio, Kuhle, Jens, Benkert, Pascal, Lorscheider, Johannes, Zecca, Chiara, Iglesias-Urrutia, Cynthia P, Manca, Andrea, Furukawa, Toshi A, Cipriani, Andrea, and Salanti, Georgia

Subjects
Methodology (stat.ME), FOS: Computer and information sciences, Applications (stat.AP), 610 Medicine & health, Statistics - Applications, 360 Social problems & social services, Statistics - Methodology, Education
Abstract

In network meta-analysis (NMA), we synthesize all relevant evidence about health outcomes with competing treatments. The evidence may come from randomized clinical trials (RCT) or non-randomized studies (NRS) as individual participant data (IPD) or as aggregate data (AD). We present a suite of Bayesian NMA and network meta-regression (NMR) models allowing for cross-design and cross-format synthesis. The models integrate a three-level hierarchical model for synthesizing IPD and AD into four approaches. The four approaches account for differences in the design and risk of bias (RoB) in the RCT and NRS evidence. These four approaches variously ignoring differences in RoB, using NRS to construct penalized treatment effect priors and bias-adjustment models that control the contribution of information from high RoB studies in two different ways. We illustrate the methods in a network of three pharmacological interventions and placebo for patients with relapsing-remitting multiple sclerosis. The estimated relative treatment effects do not change much when we accounted for differences in design and RoB. Conducting network meta-regression showed that intervention efficacy decreases with increasing participant age. We also re-analysed a network of 431 RCT comparing 21 antidepressants, and we did not observe material changes in intervention efficacy when adjusting for studies' high RoB. We re-analysed both case studies accounting for different study RoB. In summary, the described suite of NMA/NMR models enables inclusion of all relevant evidence while incorporating information on the within-study bias in both observational and experimental data and enabling estimation of individualized treatment effects through the inclusion of participant characteristics. This article is protected by copyright. All rights reserved.

Published
2023

55. Short-Term Irisin Treatment Enhanced Neurotrophin Expression Differently in the Hippocampus and the Prefrontal Cortex of Young Mice

Author

Dicarlo, Manuela, primary, Pignataro, Patrizia, additional, Zerlotin, Roberta, additional, Suriano, Clelia, additional, Zecca, Chiara, additional, Dell’Abate, Maria Teresa, additional, Storlino, Giuseppina, additional, Oranger, Angela, additional, Sanesi, Lorenzo, additional, Mori, Giorgio, additional, Grano, Maria, additional, Colaianni, Graziana, additional, and Colucci, Silvia, additional

Published
2023
Full Text
View/download PDF

57. Coexisting Logopenic Variant of Primary Progressive Aphasia with Amyloid Pathology and Early Parkinsonism

Author

Caccamo, Martina, Urso, Daniele, Nanni, Alfredo Gabriele, Gnoni, Valentina, Giugno, Alessia, Vitulli, Alessandra, Vilella, Davide, Zecca, Chiara, Dell’Abate, Maria Teresa, Anastasia, Antonio, De Blasi, Roberto, Introna, Alessandro, and Logroscino, Giancarlo

Abstract

The presence of parkinsonism features in primary progressive aphasia (PPA) is a subject of ongoing research. These features are usually more pronounced in the advanced stages of the disease, particularly in the non-fluent/agrammatic subtype, and are exceptionally rare in the logopenic variant (lvPPA). Here we report a case of a 63-year-old man presenting as language impairment, predominantly naming and word-finding difficulties, emerged alongside a left-sided internal tremor. Neurological examination revealed bilateral, left-side predominant rigidity, bradykinesia, and resting tremor. Notably, anosmia and constipation were present. Language assessments showed preserved single-word comprehension, object knowledge, and a minimal apraxia of speech, as well as sentence repetition issues. Neuroimaging and biomarker analysis supported a diagnosis of primary progressive logopenic aphasia with amyloid pathology co-existing with prominent and early parkinsonism. This case underlines the intricate relationship between language disorders, parkinsonism, and amyloid pathology in lvPPA.

Published
2024
Full Text
View/download PDF

58. Clinical and genetic analyses of familial and sporadic frontotemporal dementia patients in Southern Italy

Author

Capozzo, Rosa, Sassi, Celeste, Hammer, Monia B., Arcuti, Simona, Zecca, Chiara, Barulli, Maria R., Tortelli, Rosanna, Gibbs, J. Raphael, Crews, Cynthia, Seripa, Davide, Carnicella, Francesco, Dell'Aquila, Claudia, Rossi, Marco, Tamma, Filippo, Valluzzi, Francesco, Brancasi, Bruno, Panza, Francesco, Singleton, Andrew B., and Logroscino, Giancarlo

Published
2017
Full Text
View/download PDF

60. Calcitonin gene-related peptide antagonists in pregnancy: a disproportionality analysis in VigiBase®.

Author

Noseda, Roberta, Bedussi, Francesca, Gobbi, Claudio, Ceschi, Alessandro, and Zecca, Chiara

Subjects
DATABASES, CONFIDENCE intervals, NEUROPEPTIDES, PHARMACOLOGY, CALCITONIN, PREGNANCY outcomes, DESCRIPTIVE statistics, SEROTONIN receptors, ODDS ratio, PATIENT safety, CHEMICAL inhibitors, PREGNANCY
Abstract

Background: Current evidence on the safety of calcitonin gene–related peptide antagonists (CGRP-A) in pregnancy for the treatment of both episodic and chronic migraine is scarce and does not yet provide definitive information. By querying VigiBase®, the World Health Organization global pharmacovigilance database, this study aimed to detect differences in the reporting frequency between CGRP-A and triptans in relation to pregnancy. Methods: Disproportionality analyses on de-duplicated safety reports collected in VigiBase® as of 31.05.2023 reporting exposure to CGRP-A in pregnancy with or without pregnancy outcomes. A Reporting Odds Ratio (ROR) with a 95% confidence interval (CI) was used as a measure of disproportionality and the threshold for the detection of a signal of disproportionate reporting was set with a 95% CI lower limit > 1. Findings: Four hundred sixty-seven safety reports reported exposure to CGRP-A in pregnancy, mostly originating from the United States of America (360/467, 77%), more frequently reported by patients (225/467, 48%), who were mainly females (431/467, 92%), and more frequently reported exposure to CGRP-A during pregnancy (400/467, 86%). Compared to triptans, no signals of disproportionate reporting were detected with CGRP-A either for the overall reporting of pregnancy-related safety reports (ROR 0.91, 95% CI 0.78–1.06), for the reporting of pregnancy outcomes (maternal and/or foetal/neonatal, ROR 0.54, 95% CI 0.45–0.66), or for the reporting of foetal/neonatal outcomes (ROR 0.53, 95% CI 0.41–0.68). Conclusions: This study showed that, to date, there are no signals of increased reporting with CGRP-A compared to triptans in relation to pregnancy in VigiBase®. Future pharmacovigilance studies are needed to confirm these findings. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

61. Survival in Incident Cases with Frontotemporal Lobar Degeneration: A Registry-Based Study.

Author

Borroni, Barbara, Urso, Daniele, Zecca, Chiara, Binetti, Giuliano, Fostinelli, Silvia, Benussi, Luisa, Ghidoni, Roberta, Tarantino, Barbara, Rivolta, Jasmine, Dell'Abate, Maria Teresa, Alberici, Antonella, and Logroscino, Giancarlo

Subjects
FRONTOTEMPORAL lobar degeneration, ALZHEIMER'S disease, SURVIVAL rate, DISEASE duration, FRONTOTEMPORAL dementia
Abstract

Population-based registries represent a unique sample to estimate survival. The aim of the present study was to assess survival rates and predictors of outcome in incidental frontotemporal lobar degeneration (FTLD). Incident cases with FTLD, included between January 1, 2017 to December 31, 2017, have been followed for five years. Median survival was 8.16 years from disease onset and 5.38 years from diagnosis. Survival rates did not differ between phenotypes. Shorter disease duration from onset to diagnosis was associated with poorer outcome (p = 0.01). FTLD is a relatively homogeneous disease in terms of survival. Future multinational population-based studies are needed to confirm these findings. [ABSTRACT FROM AUTHOR]

Published
2023
Full Text
View/download PDF

62. Neurologic complications of acute hepatitis E virus infection

Author

Ripellino, Paolo, Pasi, Emanuela, Melli, Giorgia, Staedler, Claudio, Fraga, Monserrat, Moradpour, Darius, Sahli, Roland, Aubert, Vincent, Martinetti, Gladys, Bihl, Florian, Bernasconi, Enos, Terziroli Beretta-Piccoli, Benedetta, Cerny, Andreas, Dalton, Harry Roland, Zehnder, Cinzia, Mathis, Barbara, Zecca, Chiara, Disanto, Giulio, Kaelin-Lang, Alain, and Gobbi, Claudio

Published
2020
Full Text
View/download PDF

63. Clinically relevant cranio-caudal patterns of cervical cord atrophy evolution in MS

Author

Rocca, Maria A., Valsasina, Paola, Meani, Alessandro, Gobbi, Claudio, Zecca, Chiara, Rovira, Àlex, Montalban, Xavier, Kearney, Hugh, Ciccarelli, Olga, Matthews, Lucy, Palace, Jacqueline, Gallo, Antonio, Bisecco, Alvino, Gass, Achim, Eisele, Philipp, Lukas, Carsten, Bellenberg, Barbara, Barkhof, Frederik, Vrenken, Hugo, Preziosa, Paolo, Comi, Giancarlo, and Filippi, Massimo

Published
2019
Full Text
View/download PDF

64. Incidence of syndromes associated with Frontotemporal Lobar Degeneration (S19.004)

Author

Logroscino, Giancarlo, primary, Piccininni, Marco, additional, Graff, Caroline, additional, Hardiman, Orla, additional, Ludolph, Albert, additional, Moreno, Fermin, additional, Otto, Markus, additional, Remes, Anne, additional, Rowe, James, additional, Seelaar, Harro, additional, Solje, Eino, additional, Stefanova, Elka, additional, Traykov, Latchezar, additional, Jelic, Vesna, additional, Rydell, Melissa Thaeri, additional, Pender, Niall, additional, Anderl-Straub, Sarah, additional, Barandiaran, Myriam, additional, Gabilondo, Alazne, additional, Kruger, Johanna, additional, Murley, Alexander, additional, Rittman, Timothy, additional, van der Ende, Emma L., additional, Van Swieten, John, additional, Hartikainen, Paivi, additional, Stojmenovic, Gorana Mandic, additional, Meherabian, Shima, additional, Benussi, Luisa, additional, Alberici, Antonella, additional, Dell’Abate, Maria Teresa, additional, Zecca, Chiara, additional, and Borroni, Barbara, additional

Published
2023
Full Text
View/download PDF

65. Serum Glial Fibrillary Acidic Protein compared with Neurofilament Light Chain as Biomarker for Multiple Sclerosis Disease Progression (P5-3.016)

Author

Meier, Stephanie, primary, Benkert, Pascal, additional, Maceski, Aleksandra Maleska, additional, Schaedelin, Sabine, additional, Oechtering, Johanna, additional, Melie-Garcia, Lester, additional, Cagol, Alessandro, additional, Barakovic, Muhamed, additional, Galbusera, Riccardo, additional, Achtnichts, Lutz, additional, Lalive, Patrice H., additional, Bridel, Claire, additional, Müller, Stefanie, additional, Pot, Caroline, additional, Salmen, Anke, additional, Disanto, Giulio, additional, Zecca, Chiara, additional, Abdelhak, Ahmed, additional, Barro, Christian, additional, Thebault, Simon, additional, D’Souza, Marcus, additional, Derfuss, Tobias, additional, Orleth, Annette, additional, Khalil, Michael, additional, Yaldizli, Özguer, additional, Hermesdorf, Marco, additional, Wiendl, Heinz, additional, Piehl, Fredrik, additional, Fischer, Urs, additional, Kappos, Ludwig, additional, Gobbi, Claudio, additional, Granziera, Cristina, additional, Leppert, David, additional, Willemse, Eline A.J., additional, and Kuhle, Jens, additional

Published
2023
Full Text
View/download PDF

67. Once-Daily Subcutaneous Irisin Administration Mitigates Depression- and Anxiety-like Behavior in Young Mice

Author

Pignataro, Patrizia, primary, Dicarlo, Manuela, additional, Suriano, Clelia, additional, Sanesi, Lorenzo, additional, Zerlotin, Roberta, additional, Storlino, Giuseppina, additional, Oranger, Angela, additional, Zecca, Chiara, additional, Dell’Abate, Maria Teresa, additional, Mori, Giorgio, additional, Grano, Maria, additional, Colucci, Silvia, additional, and Colaianni, Graziana, additional

Published
2023
Full Text
View/download PDF

69. Serum Glial Fibrillary Acidic Protein Compared With Neurofilament Light Chain as a Biomarker for Disease Progression in Multiple Sclerosis

Author

Meier, Stephanie, primary, Willemse, Eline A.J., additional, Schaedelin, Sabine, additional, Oechtering, Johanna, additional, Lorscheider, Johannes, additional, Melie-Garcia, Lester, additional, Cagol, Alessandro, additional, Barakovic, Muhamed, additional, Galbusera, Riccardo, additional, Subramaniam, Suvitha, additional, Barro, Christian, additional, Abdelhak, Ahmed, additional, Thebault, Simon, additional, Achtnichts, Lutz, additional, Lalive, Patrice, additional, Müller, Stefanie, additional, Pot, Caroline, additional, Salmen, Anke, additional, Disanto, Giulio, additional, Zecca, Chiara, additional, D’Souza, Marcus, additional, Orleth, Annette, additional, Khalil, Michael, additional, Buchmann, Arabella, additional, Du Pasquier, Renaud, additional, Yaldizli, Özgür, additional, Derfuss, Tobias, additional, Berger, Klaus, additional, Hermesdorf, Marco, additional, Wiendl, Heinz, additional, Piehl, Fredrik, additional, Battaglini, Marco, additional, Fischer, Urs, additional, Kappos, Ludwig, additional, Gobbi, Claudio, additional, Granziera, Cristina, additional, Bridel, Claire, additional, Leppert, David, additional, Maleska Maceski, Aleksandra, additional, Benkert, Pascal, additional, and Kuhle, Jens, additional

Published
2023
Full Text
View/download PDF

70. Incidence of Syndromes Associated With Frontotemporal Lobar Degeneration in 9 European Countries

Author

Logroscino, Giancarlo, Piccininni, Marco, Graff, Caroline, Hardiman, Orla, Ludolph, Albert C., Moreno, Fermin, Otto, Markus, Remes, Anne M., Rowe, James B., Seelaar, Harro, Solje, Eino, Stefanova, Elka, Traykov, Latchezar, Jelic, Vesna, Rydell, Melissa Taheri, Pender, Niall, Anderl-Straub, Sarah, Barandiaran, Myriam, Gabilondo, Alazne, Krüger, Johanna, Murley, Alexander G., Rittman, Timothy, Van Der Ende, Emma L., Van Swieten, John C., Hartikainen, Päivi, Stojmenović, Gorana Mandić, Mehrabian, Shima, Benussi, Luisa, Alberici, Antonella, Dell'abate, Maria Teresa, Zecca, Chiara, Borroni, Barbara, Logroscino, Giancarlo, Piccininni, Marco, Graff, Caroline, Hardiman, Orla, Ludolph, Albert C., Moreno, Fermin, Otto, Markus, Remes, Anne M., Rowe, James B., Seelaar, Harro, Solje, Eino, Stefanova, Elka, Traykov, Latchezar, Jelic, Vesna, Rydell, Melissa Taheri, Pender, Niall, Anderl-Straub, Sarah, Barandiaran, Myriam, Gabilondo, Alazne, Krüger, Johanna, Murley, Alexander G., Rittman, Timothy, Van Der Ende, Emma L., Van Swieten, John C., Hartikainen, Päivi, Stojmenović, Gorana Mandić, Mehrabian, Shima, Benussi, Luisa, Alberici, Antonella, Dell'abate, Maria Teresa, Zecca, Chiara, and Borroni, Barbara

Abstract

Importance: Diagnostic incidence data for syndromes associated with frontotemporal lobar degeneration (FTLD) in multinational studies are urgent in light of upcoming therapeutic approaches. Objective: To assess the incidence of FTLD across Europe. Design, Setting, and Participants: The Frontotemporal Dementia Incidence European Research Study (FRONTIERS) was a retrospective cohort study conducted from June 1, 2018, to May 31, 2019, using a population-based registry from 13 tertiary FTLD research clinics from the UK, the Netherlands, Finland, Sweden, Spain, Bulgaria, Serbia, Germany, and Italy and including all new FTLD-associated cases during the study period, with a combined catchment population of 11023643 person-years. Included patients fulfilled criteria for the behavioral variant of frontotemporal dementia (BVFTD), the nonfluent variant or semantic variant of primary progressive aphasia (PPA), unspecified PPA, progressive supranuclear palsy, corticobasal syndrome, or frontotemporal dementia with amyotrophic lateral sclerosis (FTD-ALS). Data were analyzed from July 19 to December 7, 2021. Main Outcomes and Measures: Random-intercept Poisson models were used to obtain estimates of the European FTLD incidence rate accounting for geographic heterogeneity. Results: Based on 267 identified cases (mean [SD] patient age, 66.70 [9.02] years; 156 males [58.43%]), the estimated annual incidence rate for FTLD in Europe was 2.36 cases per 100000 person-years (95% CI, 1.59-3.51 cases per 100000 person-years). There was a progressive increase in FTLD incidence across age, reaching its peak at the age of 71 years, with 13.09 cases per 100 000 person-years (95% CI, 8.46-18.93 cases per 100 000 person-years) among men and 7.88 cases per 100 000 person-years (95% CI, 5.39-11.60 cases per 100 000 person-years) among women. Overall, the incidence was higher among men (2.84 cases per 100000 person-years; 95% CI, 1.88-4.27 cases per 100000 person-years) than among women (1.91 case

Published
2023

71. Safety profile of monoclonal antibodies targeting the calcitonin gene-related peptide system in pregnancy: Updated analysis in VigiBase®

Author

Noseda, Roberta; https://orcid.org/0000-0002-4946-7926, Bedussi, Francesca, Gobbi, Claudio; https://orcid.org/0000-0002-7554-0664, Ceschi, Alessandro; https://orcid.org/0000-0002-4308-0405, Zecca, Chiara; https://orcid.org/0000-0002-9990-3431, Noseda, Roberta; https://orcid.org/0000-0002-4946-7926, Bedussi, Francesca, Gobbi, Claudio; https://orcid.org/0000-0002-7554-0664, Ceschi, Alessandro; https://orcid.org/0000-0002-4308-0405, and Zecca, Chiara; https://orcid.org/0000-0002-9990-3431

Abstract

Background: Safety data on the use of migraine preventive monoclonal antibodies targeting the calcitonin gene-related peptide (CGRP) system in pregnancy are limited. Methods: Updated pharmacovigilance assessment of the safety reports related to pregnancy associated with erenumab, galcanezumab, fremanezumab and eptinezumab, retrieved from VigiBase® as of 31 December 2021. As primary outcome, the whole group of monoclonal antibodies targeting the CGRP system was considered and sex and age subgroup disproportionality analyses using the reporting odds ratio (ROR) were conducted. Results: 286 safety reports were found: 116 (40.6%) on erenumab, 125 (43.7%) on galcanezumab, 39 (13.6%) on fremanezumab, 6 (2.1%) on eptinezumab. One hundred and forty-nine (52.1%) safety reports reported only drug exposure in relation to pregnancy while 137 (47.9%) also included ≥1 pregnancy outcomes: maternal outcomes (n = 64), spontaneous abortion (n = 63), foetal growth restriction (n = 1), prematurity (n = 8), neonatal outcomes (n = 13), and poor breastfeeding (n = 1). No specific patterns of maternal, foetal and neonatal toxicity were observed. Spontaneous abortion was not disproportionally more frequently reported with erenumab, galcanezumab, fremanezumab and eptinezumab compared with the entire database (ROR 1.1, 95% confidence interval, CI, 0.8–1.5), the entire database since 2018 (ROR 1.3, 95% CI 1.0–1.8), and triptans (ROR 1.2, 95% CI 0.8–1.9). Conclusions: This updated safety analysis on erenumab, galcanezumab, fremanezumab and eptinezumab in pregnancy showed no signals of foeto-maternal toxicity according to VigiBase® safety reports.

Published
2023

72. Digital health for chronic disease management: An exploratory method to investigating technology adoption potential

Author

Nittas, Vasileios; https://orcid.org/0000-0002-6685-8275, Zecca, Chiara; https://orcid.org/0000-0002-9990-3431, Kamm, Christian P; https://orcid.org/0000-0002-3906-0161, Kuhle, Jens, Chan, Andrew, von Wyl, Viktor, Nittas, Vasileios; https://orcid.org/0000-0002-6685-8275, Zecca, Chiara; https://orcid.org/0000-0002-9990-3431, Kamm, Christian P; https://orcid.org/0000-0002-3906-0161, Kuhle, Jens, Chan, Andrew, and von Wyl, Viktor

Abstract

INTRODUCTION The availability of consumer-facing health technologies for chronic disease management is skyrocketing, yet most are limited by low adoption rates. Improving adoption requires a better understanding of a target population's previous exposure to technology. We propose a low-resource approach of capturing and clustering technology exposure, as a mean to better understand patients and target health technologies. METHODS Using Multiple Sclerosis (MS) as a case study, we applied exploratory multivariate factorial analyses to survey data from the Swiss MS Registry. We calculated individual-level factor scorings, aiming to investigate possible technology adoption clusters with similar digital behavior patterns. The resulting clusters were transformed using radar and then compared across sociodemographic and health status characteristics. RESULTS Our analysis included data from 990 respondents, resulting in three clusters, which we defined as the (1) average users, (2) health-interested users, and (3) low frequency users. The average user uses consumer-facing technology regularly, mainly for daily, regular activities and less so for health-related purposes. The health-interested user also uses technology regularly, for daily activities as well as health-related purposes. The low-frequency user uses technology infrequently. CONCLUSIONS Only about 10% of our sample has been regularly using (adopting) consumer-facing technology for MS and health-related purposes. That might indicate that many of the current consumer-facing technologies for MS are only attractive to a small proportion of patients. The relatively low-resource exploratory analyses proposed here may allow for a better characterization of prospective user populations and ultimately, future patient-facing technologies that will be targeted to a broader audience.

Published
2023

74. Neurofilament Light Chain Elevation and Disability Progression in Multiple Sclerosis

Author

Abdelhak, Ahmed, Benkert, Pascal, Schaedelin, Sabine, Boscardin, W. John, Cordano, Christian, Oechtering, Johanna, Ananth, Kirtana, Granziera, Cristina, Melie-Garcia, Lester, Montes, Shivany Condor, Beaudry-Richard, Alexandra, Achtnichts, Lutz, Oertel, Frederike C., Lalive, Patrice H., Leppert, David, Müller, Stefanie, Henry, Roland G., Pot, Caroline, Matthias, Amandine, Salmen, Anke, Oksenberg, Jorge R., Disanto, Giulio, Zecca, Chiara, D’Souza, Marcus, Du Pasquier, Renaud, Bridel, Claire, Gobbi, Claudio, Kappos, Ludwig, Hauser, Stephen L., Cree, Bruce A. C., Kuhle, Jens, and Green, Ari J.

Abstract

IMPORTANCE: Mechanisms contributing to disability accumulation in multiple sclerosis (MS) are poorly understood. Blood neurofilament light chain (NfL) level, a marker of neuroaxonal injury, correlates robustly with disease activity in people with MS (MS); however, data on the association between NfL level and disability accumulation have been conflicting. OBJECTIVE: To determine whether and when NfL levels are elevated in the context of confirmed disability worsening (CDW). DESIGN, SETTING, AND PARTICIPANTS: This study included 2 observational cohorts: results from the Expression, Proteomics, Imaging, Clinical (EPIC) study at the University of California San Francisco (since 2004) were confirmed in the Swiss Multiple Sclerosis Cohort (SMSC), a multicenter study in 8 centers since 2012. Data were extracted from EPIC in April 2022 (sampling July 1, 2004, to December 20, 2016) and SMSC in December 2022 (sampling June 6, 2012, to September 2, 2021). The study included 2 observational cohorts in tertiary MS centers. All participants of both cohorts with available NfL results were included in the study, and no eligible participants were excluded or declined to participate. EXPOSURE: Association between NfL z scores and CDW. MAIN OUTCOME MEASURES: CDW was defined as Expanded Disability Status Scale (EDSS) worsening that was confirmed after 6 or more months and classified into CDW associated with clinical relapses (CDW-R) or independent of clinical relapses (CDW-NR). Visits were classified in relation to the disability worsening events into CDW(−2) for 2 visits preceding event, CDW(−1) for directly preceding event, CDW(event) for first diagnosis of EDSS increase, and the confirmation visit. Mixed linear and Cox regression models were used to evaluate NfL dynamics and to assess the association of NfL with future CDW, respectively. RESULTS: A total of 3906 EPIC visits (609 participants; median [IQR] age, 42.0 [35.0-50.0] years; 424 female [69.6%]) and 8901 SMSC visits (1290 participants; median [IQR] age, 41.2 [32.5-49.9] years; 850 female [65.9%]) were included. In CDW-R (EPIC, 36 events; SMSC, 93 events), NfL z scores were 0.71 (95% CI, 0.35-1.07; P < .001) units higher at CDW-R(−1) in EPIC and 0.32 (95% CI, 0.14-0.49; P < .001) in SMSC compared with stable MS samples. NfL elevation could be detected preceding CDW-NR (EPIC, 191 events; SMSC, 342 events) at CDW-NR(−2) (EPIC: 0.23; 95% CI, 0.01-0.45; P = .04; SMSC: 0.28; 95% CI, 0.18-0.37; P < .001) and at CDW-NR(−1) (EPIC: 0.27; 95% CI, 0.11-0.44; P < .001; SMSC: 0.09; 95% CI, 0-0.18; P = .06). Those findings were replicated in the subgroup with relapsing-remitting MS. Time-to-event analysis confirmed the association between NfL levels and future CDW-R within approximately 1 year and CDW-NR (in approximately 1-2 years). CONCLUSIONS AND RELEVANCE: This cohort study documents the occurrence of NfL elevation in advance of clinical worsening and may hint to a potential window of ongoing dynamic central nervous system pathology that precedes the diagnosis of CDW.

Published
2023
Full Text
View/download PDF

78. Engagement in volunteering activities by persons with multiple sclerosis in Switzerland

Author

Mettler, Mathias, primary, Stanikić, Mina, additional, Schwegler, Urban, additional, Sieber, Chloé, additional, Ajdacic-Gross, Vladeta, additional, Rodgers, Stephanie, additional, Haag, Christina, additional, Zecca, Chiara, additional, Calabrese, Pasquale, additional, Kägi, Susanne, additional, Rapold, Irene, additional, and von Wyl, Viktor, additional

Published
2023
Full Text
View/download PDF

80. Correlation of disability with quality of life in patients with multiple sclerosis treated with natalizumab: primary results and post hoc analysis of the TYSabri ImPROvement study (PROTYS)

Author

Achtnichts, Lutz, primary, Zecca, Chiara, additional, Findling, Oliver, additional, Kamm, Christian P, additional, Mueller, Stefanie, additional, Kuhle, Jens, additional, Lutterotti, Andreas, additional, Gobbi, Claudio, additional, Viviani, Camille, additional, Villiger-Borter, Emanuela, additional, and Nedeltchev, Krassen, additional

Published
2023
Full Text
View/download PDF

81. Specific Aspects of Immunotherapy for Multiple Sclerosis in Switzerland—A Structured Commentary, Update 2022

Author

Friedli, Christoph, primary, Salmen, Anke, additional, Hoepner, Robert, additional, Achtnichts, Lutz, additional, Bigi, Sandra, additional, Derfuss, Tobias, additional, Gobbi, Claudio, additional, Kamber, Nicole, additional, Kamm, Christian P., additional, Kuhle, Jens, additional, Lalive, Patrice, additional, Müller, Stefanie, additional, Papadopoulou, Athina, additional, Pot, Caroline, additional, Zecca, Chiara, additional, and Chan, Andrew, additional

Published
2022
Full Text
View/download PDF

83. Longitudinal Postvaccine SARS-CoV-2 Immunoglobulin G Titers, Memory B-Cell Responses, and Risk of COVID-19 in Multiple Sclerosis Over 1 Year

Author

Disanto, Giulio, primary, Galante, Alice, additional, Cantu', Marco, additional, Sacco, Rosaria, additional, Mele, Federico, additional, Eisler, Jennifer Jessica, additional, Keller, Franco, additional, Bernasconi, Enos, additional, Sallusto, Federica, additional, Zecca, Chiara, additional, and Gobbi, Claudio, additional

Published
2022
Full Text
View/download PDF

84. The Real-World Experiences of Persons With Multiple Sclerosis During the First COVID-19 Lockdown: Application of Natural Language Processing

Author

Chiavi, Deborah, primary, Haag, Christina, additional, Chan, Andrew, additional, Kamm, Christian Philipp, additional, Sieber, Chloé, additional, Stanikić, Mina, additional, Rodgers, Stephanie, additional, Pot, Caroline, additional, Kesselring, Jürg, additional, Salmen, Anke, additional, Rapold, Irene, additional, Calabrese, Pasquale, additional, Manjaly, Zina-Mary, additional, Gobbi, Claudio, additional, Zecca, Chiara, additional, Walther, Sebastian, additional, Stegmayer, Katharina, additional, Hoepner, Robert, additional, Puhan, Milo, additional, and von Wyl, Viktor, additional

Published
2022
Full Text
View/download PDF

85. Association of age and disease duration with comorbidities and disability: A study of the Swiss Multiple Sclerosis Registry

Author

Stanikić, Mina, primary, Salmen, Anke, additional, Chan, Andrew, additional, Kuhle, Jens, additional, Kaufmann, Marco, additional, Ammann, Sabin, additional, Schafroth, Sandra, additional, Rodgers, Stephanie, additional, Haag, Christina, additional, Pot, Caroline, additional, Kamm, Christian P, additional, Zecca, Chiara, additional, Gobbi, Claudio, additional, Calabrese, Pasquale, additional, Manjaly, Zina-Mary, additional, and von Wyl, Viktor, additional

Published
2022
Full Text
View/download PDF

86. sj-pdf-4-cep-10.1177_03331024231158083 - Supplemental material for Safety profile of monoclonal antibodies targeting the calcitonin gene-related peptide system in pregnancy: Updated analysis in VigiBase®

Author

Noseda, Roberta, Bedussi, Francesca, Gobbi, Claudio, Ceschi, Alessandro, and Zecca, Chiara

Subjects
FOS: Psychology, FOS: Clinical medicine, 170199 Psychology not elsewhere classified, 110319 Psychiatry (incl. Psychotherapy), 110306 Endocrinology, 111599 Pharmacology and Pharmaceutical Sciences not elsewhere classified, 110904 Neurology and Neuromuscular Diseases, Neuroscience
Abstract

Supplemental material, sj-pdf-4-cep-10.1177_03331024231158083 for Safety profile of monoclonal antibodies targeting the calcitonin gene-related peptide system in pregnancy: Updated analysis in VigiBase® by Roberta Noseda, Francesca Bedussi, Claudio Gobbi, Alessandro Ceschi and Chiara Zecca in Cephalalgia

Published
2023
Full Text
View/download PDF

87. Response to erenumab assessed by HIT-6 is modulated by genetic factors and arterial hypertension - an explorative cohort study

Author

Zecca, Chiara, Terrazzino, Salvatore, Para, Davide, Campagna, Giovanna, Viana, Michele, Schankin, Christoph J, and Gobbi, Claudio

Subjects
610 Medicine & health
Abstract

BACKGROUND Response predictors to erenumab (ERE) in migraine patients would benefit their clinical management. We investigate associations between patients' clinic characteristics and polymorphisms at CALCRL and RAMP1 genes and response to ERE treatment measured as clinically meaningful improvement of the headache impact test 6 (HIT-6) score. METHODS Post-hoc analysis of a prospective, multicenter, investigator-initiated study involving 110 migraine patients starting ERE 70 mg/month. Demographics, medical history, and migraine-related burden measured by HIT-6 score were collected during 3 months before and after ERE start. Selected polymorphic variants of calcitonin receptor-like receptor and receptor activity-modifying protein-1 genes were determined using Real-time PCR. Logistic regression models identified independent predictors for response to ERE, defined as HIT-6 score improvement ≥8 points (HIT-6 responders [HIT-6RESP], vs. HIT-6 non-responders [HIT-6NRESP]). RESULTS At month 3, 58 (52.7%) patients were HIT-6RESP. Comorbid hypertension predicted a lower probability of being HIT-6RESP [OR (95%CI] 0.160 (0.047-0.548), p=0.003). Compared to major alleles, minor alleles CALCRL rs6710852G and RAMP rs6431564G conferred an increased probability of being HIT-6RESP [for each G allele: OR (95%CI): 2.82(1.03-7.73), p=0.043; OR 95%CI): 2.10(1.05-4.22), p=0.037]. RAMP1 rs13386048A and RAMP1 rs12465864G decreased this probability [for each rs13386048A, OR (95%CI): 0.53(0.28-0.98), p=0.042; for each rs12465864G, OR(95%CI): 0.32(0.13-0.75), p=0.009). A genetic risk score based on the presence and number of identified risk alleles resulted independently associated with HIT-6RESP (OR, 0.49; 95%CI, 0.33-0.72; p= 0.0003) surviving Bonferroni's correction. CONCLUSIONS Response to ERE was associated with comorbid hypertension and specific allelic variants at CALCRL and RAMP1 genes. Results require confirmation in future studies.

Published
2023
Full Text
View/download PDF

88. sj-pdf-3-cep-10.1177_03331024231158083 - Supplemental material for Safety profile of monoclonal antibodies targeting the calcitonin gene-related peptide system in pregnancy: Updated analysis in VigiBase®

Author

Noseda, Roberta, Bedussi, Francesca, Gobbi, Claudio, Ceschi, Alessandro, and Zecca, Chiara

Subjects
FOS: Psychology, FOS: Clinical medicine, 170199 Psychology not elsewhere classified, 110319 Psychiatry (incl. Psychotherapy), 110306 Endocrinology, 111599 Pharmacology and Pharmaceutical Sciences not elsewhere classified, 110904 Neurology and Neuromuscular Diseases, Neuroscience
Abstract

Supplemental material, sj-pdf-3-cep-10.1177_03331024231158083 for Safety profile of monoclonal antibodies targeting the calcitonin gene-related peptide system in pregnancy: Updated analysis in VigiBase® by Roberta Noseda, Francesca Bedussi, Claudio Gobbi, Alessandro Ceschi and Chiara Zecca in Cephalalgia

Published
2023
Full Text
View/download PDF

89. sj-pdf-1-cep-10.1177_03331024231158083 - Supplemental material for Safety profile of monoclonal antibodies targeting the calcitonin gene-related peptide system in pregnancy: Updated analysis in VigiBase®

Author

Noseda, Roberta, Bedussi, Francesca, Gobbi, Claudio, Ceschi, Alessandro, and Zecca, Chiara

Subjects
FOS: Psychology, FOS: Clinical medicine, 170199 Psychology not elsewhere classified, 110319 Psychiatry (incl. Psychotherapy), 110306 Endocrinology, 111599 Pharmacology and Pharmaceutical Sciences not elsewhere classified, 110904 Neurology and Neuromuscular Diseases, Neuroscience
Abstract

Supplemental material, sj-pdf-1-cep-10.1177_03331024231158083 for Safety profile of monoclonal antibodies targeting the calcitonin gene-related peptide system in pregnancy: Updated analysis in VigiBase® by Roberta Noseda, Francesca Bedussi, Claudio Gobbi, Alessandro Ceschi and Chiara Zecca in Cephalalgia

Published
2023
Full Text
View/download PDF

90. sj-pdf-2-cep-10.1177_03331024231158083 - Supplemental material for Safety profile of monoclonal antibodies targeting the calcitonin gene-related peptide system in pregnancy: Updated analysis in VigiBase®

Author

Noseda, Roberta, Bedussi, Francesca, Gobbi, Claudio, Ceschi, Alessandro, and Zecca, Chiara

Subjects
FOS: Psychology, FOS: Clinical medicine, 170199 Psychology not elsewhere classified, 110319 Psychiatry (incl. Psychotherapy), 110306 Endocrinology, 111599 Pharmacology and Pharmaceutical Sciences not elsewhere classified, 110904 Neurology and Neuromuscular Diseases, Neuroscience
Abstract

Supplemental material, sj-pdf-2-cep-10.1177_03331024231158083 for Safety profile of monoclonal antibodies targeting the calcitonin gene-related peptide system in pregnancy: Updated analysis in VigiBase® by Roberta Noseda, Francesca Bedussi, Claudio Gobbi, Alessandro Ceschi and Chiara Zecca in Cephalalgia

Published
2023
Full Text
View/download PDF

91. Spinal cord lesions and brain grey matter atrophy independently predict clinical worsening in definite multiple sclerosis: a 5-year, multicentre study

Author

Rocca, Maria A, primary, Valsasina, Paola, additional, Meani, Alessandro, additional, Gobbi, Claudio, additional, Zecca, Chiara, additional, Barkhof, Frederik, additional, Schoonheim, Menno M, additional, Strijbis, Eva M, additional, Vrenken, Hugo, additional, Gallo, Antonio, additional, Bisecco, Alvino, additional, Ciccarelli, Olga, additional, Yiannakas, Marios, additional, Rovira, Alex, additional, Sastre-Garriga, Jaume, additional, Palace, Jacqueline, additional, Matthews, Lucy, additional, Gass, Achim, additional, Eisele, Philipp, additional, Lukas, Carsten, additional, Bellenberg, Barbara, additional, Margoni, Monica, additional, Preziosa, Paolo, additional, and Filippi, Massimo, additional

Published
2022
Full Text
View/download PDF

93. Genotype-phenotype correlation in the spectrum of frontotemporal dementia-parkinsonian syndromes and advanced diagnostic approaches.

Author

Zecca, Chiara, Tortelli, Rosanna, Carrera, Paola, Dell'Abate, Maria Teresa, Logroscino, Giancarlo, and Ferrari, Maurizio

Subjects
*GENETIC mutation, *GENETICS, *SEQUENCE analysis, *GENOME-wide association studies, *GENOTYPES, *PARKINSONIAN disorders, *FRONTOTEMPORAL dementia, *PHENOTYPES
Abstract

The term frontotemporal dementia (FTD) refers to a group of progressive neurodegenerative disorders characterized mainly by atrophy of the frontal and anterior temporal lobes. Based on clinical presentation, three main clinical syndromes have traditionally been described: behavioral variant frontotemporal dementia (bvFTD), non-fluent/agrammatic primary progressive aphasia (nfPPA), and semantic variant PPA (svPPA). However, over the last 20 years, it has been recognized that cognitive phenotypes often overlap with motor phenotypes, either motor neuron diseases or parkinsonian signs and/or syndromes like progressive supranuclear palsy (PSP) and cortico-basal syndrome (CBS). Furthermore, FTD-related genes are characterized by genetic pleiotropy and can cause, even in the same family, pure motor phenotypes, findings that underlie the clinical continuum of the spectrum, which has pure cognitive and pure motor phenotypes as the extremes. The genotype-phenotype correlation of the spectrum, FTD-motor neuron disease, has been well defined and extensively investigated, while the continuum, FTD-parkinsonism, lacks a comprehensive review. In this narrative review, we describe the current knowledge about the genotype-phenotype correlation of the spectrum, FTD-parkinsonism, focusing on the phenotypes that are less frequent than bvFTD, namely nfPPA, svPPA, PSP, CBS, and cognitive-motor overlapping phenotypes (i.e. PPA + PSP). From a pathological point of view, they are characterized mainly by the presence of phosphorylated-tau inclusions, either 4 R or 3 R. The genetic correlate of the spectrum can be heterogeneous, although some variants seem to lead preferentially to specific clinical syndromes. Furthermore, we critically review the contribution of genome-wide association studies (GWAS) and next-generation sequencing (NGS) in disentangling the complex heritability of the FTD-parkinsonism spectrum and in defining the genotype-phenotype correlation of the entire clinical scenario, owing to the ability of these techniques to test multiple genes, and so to allow detailed investigations of the overlapping phenotypes. Finally, we conclude with the importance of a detailed genetic characterization and we offer to patients and families the chance to be included in future randomized clinical trials focused on autosomal dominant forms of FTLD. [ABSTRACT FROM AUTHOR]

Published
2023
Full Text
View/download PDF

95. Association of Brain Atrophy With Disease Progression Independent of Relapse Activity in Patients With Relapsing Multiple Sclerosis

Author

Cagol, Alessandro, primary, Schaedelin, Sabine, additional, Barakovic, Muhamed, additional, Benkert, Pascal, additional, Todea, Ramona-Alexandra, additional, Rahmanzadeh, Reza, additional, Galbusera, Riccardo, additional, Lu, Po-Jui, additional, Weigel, Matthias, additional, Melie-Garcia, Lester, additional, Ruberte, Esther, additional, Siebenborn, Nina, additional, Battaglini, Marco, additional, Radue, Ernst-Wilhelm, additional, Yaldizli, Özgür, additional, Oechtering, Johanna, additional, Sinnecker, Tim, additional, Lorscheider, Johannes, additional, Fischer-Barnicol, Bettina, additional, Müller, Stefanie, additional, Achtnichts, Lutz, additional, Vehoff, Jochen, additional, Disanto, Giulio, additional, Findling, Oliver, additional, Chan, Andrew, additional, Salmen, Anke, additional, Pot, Caroline, additional, Bridel, Claire, additional, Zecca, Chiara, additional, Derfuss, Tobias, additional, Lieb, Johanna M., additional, Remonda, Luca, additional, Wagner, Franca, additional, Vargas, Maria I., additional, Du Pasquier, Renaud, additional, Lalive, Patrice H., additional, Pravatà, Emanuele, additional, Weber, Johannes, additional, Cattin, Philippe C., additional, Gobbi, Claudio, additional, Leppert, David, additional, Kappos, Ludwig, additional, Kuhle, Jens, additional, and Granziera, Cristina, additional

Published
2022
Full Text
View/download PDF

96. A CLEIA Antigen Assay in Diagnosis and Follow-Up of SARS-CoV-2-Positive Subjects

Author

Scarcella, Salvatore, primary, Rizzelli, Azzurra, additional, Fontana, Andrea, additional, Zecca, Chiara, additional, Pasanisi, Giancarlo, additional, Musio, Katia, additional, Putignano, Anna Laura, additional, Aprile, Valerio, additional, Fedele, Alberto, additional, Errico, Pierangelo, additional, Copetti, Massimiliano, additional, and Tassi, Vittorio, additional

Published
2022
Full Text
View/download PDF

99. Decipher non‐canonicalSPASTsplicing mutations with the help of functional assays in patients affected by spastic paraplegia 4 ( SPG4 )

Author

Ferese, Rosangela, primary, Scala, Simona, additional, Suppa, Antonio, additional, Campopiano, Rosa, additional, Asci, Francesco, additional, Chiaravalloti, Maria Antonietta, additional, Zampogna, Alessandro, additional, D'Alessio, Carmelo, additional, Fittipaldi, Filomena, additional, Buttari, Fabio, additional, Di Pardo, Alba, additional, Giardina, Emiliano, additional, Zampatti, Stefania, additional, Fornai, Francesco, additional, Novelli, Giuseppe, additional, Fanelli, Mirco, additional, Zecca, Chiara, additional, Logroscino, Giancarlo, additional, Centonze, Diego, additional, and Gambardella, Stefano, additional

Published
2022
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results